Victor Zheng
ABSTRACT
Human immunodeficiency virus (HIV) is a virus that weakens the human immune system that leads to acquired immunodeficiency syndrome (AIDS), which renders individuals more susceptible to other infections and diseases. There are currently no available cures of HIV, so more research is needed to develop cost-effective methods to seek therapeutic interventions. The purpose of this review article is to discuss the mechanistic impacts of ABX464, which is an anti-HIV drug that has been shown to decelerate HIV biogenesis. Using a publicly available database of RNA sequence repository, it can be surmised that ABX464 can increase antiviral function in macrophages by limiting the flux of major histocompatibility class I pathway. This could potentially limit the proliferation and activation of T-cells, which would be beneficial in the context of anti-HIV response, given that HIV primarily targets T-cells for its growth and proliferation. These observations indicate that ABX464 can potentially exert pleiotropic methods of suppressing viral biogenesis and activity.
Comments